華軟科技(002453.SZ):預計半年度虧損6000-8000萬元
格隆匯7月9日丨華軟科技(002453.SZ)公佈,預計半年度虧損6,000-8,000萬元,扣非虧損6,100-8,100萬元。1、去年同期,鑑於北京奧得賽化學有限公司未實現2022年度業績承諾,根據《盈利預測補償協議》及《盈利預測補償協議之補充協議》,公司於2023年上半年與部分補償義務人就業績承諾補償方案達成了一致,確認非經常性損益2.7億元。2、公司持續實施精細化管理、降本增效等措施,使公司整體毛利上升,影響本期利潤,經營情況有所改善,故扣除非經常性損益後的淨利潤較上年同期預計增長3%-27%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.